Page 56 - 《中国药科大学学报》2025年第4期

452 学报 Journal of China Pharmaceutical University 2025, 56(4): 444 − 452 第 56 卷

[39] Van Lint S, Renmans D, Broos K, et al. Intratumoral delivery of [51] Zhou XY, Pan YF, Yu LJ, et al. Feasibility of cRGD conjuga-
TriMix mRNA results in T-cell activation by cross-presenting tion at 5′-antisense strand of siRNA by phosphodiester linkage
dendritic cells[J]. Cancer Immunol Res, 2016, 4(2): 146-156. extension[J]. Mol Ther Nucleic Acids, 2021, 25: 603-612.
[40] Liu MR, Hu SQ, Yan N, et al. Inhalable extracellular vesicle de- [52] Pan YF, Zhu YJ, Ma Y, et al. Design and synthesis of nu-
livery of IL-12 mRNA to treat lung cancer and promote sys- cleotidyl lipids and their application in the targeted delivery of
temic immunity[J]. Nat Nanotechnol, 2024, 19(4): 565-575. siG12D for pancreatic cancer therapy[J]. Biomed Pharma-
[41] Terhorst D, Fossum E, Baranska A, et al. Laser-assisted intra- cother, 2024, 172: 116239.
dermal delivery of adjuvant-free vaccines targeting XCR1+ den- [53] Guo H, Hong JM, Zhu YJ, et al. A mannosylated peptidyl lipid
dritic cells induces potent antitumoral responses[J]. J Immunol, CManDA doped into cytidinyl/cationic lipids efficiently deliv-
2015, 194(12): 5895-5902. ers siG12Ss to lung cancer in vivo[J]. J Control Release, 2025,
[42] . Broderick KE, Humeau LM. Enhanced delivery of DNA or 381: 113624.
RNA vaccines by electroporation[M]//RNA Vaccines. New [54] Zhu YJ, Li X, Zhang Q, et al. Aptamer AS411 interacts with the
York, NY: Springer New York, 2016: 193-200. KRAS promoter/hnRNP A1 complex and shows increased po-
[43] Sun WQ, Xing CY, Zhao LB, et al. Ultrasound assisted exoso- tency against drug-resistant lung cancer[J]. RSC Med Chem,
mal delivery of tissue responsive mRNA for enhanced efficacy 2024, 15(5): 1515-1526.
S
S
and minimized off-target effects[J]. Mol Ther Nucleic Acids, [55] Yu J, Yu XT, Sun XD, et al. Bis-2'-F-cG A MP isomers encap-
2020, 20: 558-567. sulated in cytidinyl/cationic lipids act as potent in situ autolo-
[44] Teixeira L, Medioni J, Garibal J, et al. A first-in-human phase I gous tumor vaccines[J]. Mol Ther, 2024, 32(6): 1917-1933.
study of INVAC-1, an optimized human telomerase DNA vac- [56] Yu XT, Yu J, Dai H, et al. Novel formulation of c-di-GMP with
cine in patients with advanced solid tumors[J]. Clin Cancer Res, cytidinyl/cationic lipid reverses T cell exhaustion and activates
2020, 26(3): 588-597. stronger anti-tumor immunity[J]. Theranostics, 2022, 12(15):
[45] Schott JW, Morgan M, Galla M, et al. Viral and synthetic RNA 6723-6739.
vector technologies and applications[J]. Mol Ther, 2016, 24(9): [57] Li L, Long JR, Sang Y, et al. Rational preparation and applica-
1513-1527. tion of a mRNA delivery system with cytidinyl/cationic lipid[J].
[46] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of J Control Release, 2021, 340: 114-124.
the BNT162b2 mRNA covid-19 vaccine[J]. N Engl J Med, [58] Kim J, Eygeris Y, Gupta M, et al. Self-assembled mRNA vac-
2020, 383(27): 2603-2615. cines[J]. Adv Drug Deliv Rev, 2021, 170: 83-112.
[47] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of [59] Fang EY, Liu XH, Li M, et al. Advances in COVID-19 mRNA
the mRNA-1273 SARS-CoV-2 vaccine[J]. N Engl J Med, 2021, vaccine development[J]. Signal Transduct Target Ther, 2022,
384(5): 403-416. 7(1): 94.
[48] Guan J, Pan YF, Li HT, et al. Activity and tissue distribution of [60] Khan MM, Filipczak N, Torchilin VP. Cell penetrating pep-
antisense oligonucleotide CT102 encapsulated with tides: a versatile vector for co-delivery of drug and genes in can-
cytidinyl/cationic lipid against hepatocellular carcinoma[J]. Mol cer[J]. J Control Release, 2021, 330: 1220-1228.
Pharm, 2022, 19(12): 4552-4564. [61] Qiu YS, Man RCH, Liao QY, et al. Effective mRNA pul-
[49] Ma Y, Zhao WT, Li YD, et al. Structural optimization and addi- monary delivery by dry powder formulation of PEGylated syn-
tional targets identification of antisense oligonucleotide G3139 thetic KL4 peptide[J]. J Control Release, 2019, 314: 102-115.
encapsulated in a neutral cytidinyl-lipid combined with a cation- [62] Markov O, Oshchepkova A, Mironova N. Immunotherapy
ic lipid in vitro and in vivo[J]. Biomaterials, 2019, 197: 182- based on dendritic cell-targeted/-derived extracellular vesicles-a
193. novel strategy for enhancement of the anti-tumor immune re-
[50] Pan YF, Guan J, Gao YJ, et al. Modified ASO conjugates en- sponse[J]. Front Pharmacol, 2019, 10: 1152.
capsulated with cytidinyl/cationic lipids exhibit more potent and [63] Vlatkovic I. Non-immunotherapy application of LNP-mRNA:
longer-lasting anti-HCC effects[J]. Mol Ther Nucleic Acids, maximizing efficacy and safety[J]. Biomedicines, 2021, 9(5):
2023, 32: 807-821. 530.

专家介绍］杨振军，北京大学医学部药学院教授、天然药物及仿生药物全国重点实验室课题组
［
长。北京医科大学药学专业学士、药物化学专业理学博士，美国佐治亚大学药学院博士后。曾任
国家自然科学基金委员会化学部化学生物学流动项目主任；现担任中国化学会化学生物学和中国
药学会药物化学及核酸药物专业委员会委员、北京理化分析测试技术学会核酸适配体交叉技术分
会副理事长、江西师范大学和陕西师范大学及江西科技师范大学学术委员会委员。主要研究方向
为核酸药物的化学修饰和新型靶向制剂及化学生物学研究。主持科技部新药重大专项、973 和重
大 863 项目课题、自然基金委重点课题子课题及北京科技计划项目等，发表论文 160 多篇，申请和
授权专利 30 多项，获教育部自然科学一等奖一项、二等奖两项，国家自然科学二等奖一项。